ABSTRACT
The current HIV subjectivity lies on two great enunciative categories: HIV body, raised from Aids epidemic former stage, catheterized by being the viral genius development place. This omnipotent structure appears untouched of medical interdiction. And the ARV body, identified to H.A.A.R.T regime drugs adherence, and to horizontal and vertical machinic flows as well. These categories obtained from Flix Guattari's thoughts, are placed like theoretical framework for predicting of adherence achievement.
Subject(s)
Anti-HIV Agents/therapeutic use , HIV Seropositivity/therapy , Patient Compliance/psychology , Zidovudine/therapeutic use , Cognitive Behavioral Therapy/methods , HIV Seropositivity/drug therapy , HumansABSTRACT
The current HIV subjectivity lies on two great enunciative categories: HIV body, raised from Aids epidemic former stage, catheterized by being the viral genius development place. This omnipotent structure appears untouched of medical interdiction. And the ARV body, identified to H.A.A.R.T regime drugs adherence, and to horizontal and vertical machinic flows as well. These categories obtained from Flix Guattaris thoughts, are placed like theoretical framework for predicting of adherence achievement.
ABSTRACT
The current HIV subjectivity lies on two great enunciative categories: HIV body, raised from Aids epidemic former stage, catheterized by being the viral genius development place. This omnipotent structure appears untouched of medical interdiction. And the ARV body, identified to H.A.A.R.T regime drugs adherence, and to horizontal and vertical machinic flows as well. These categories obtained from Flix Guattaris thoughts, are placed like theoretical framework for predicting of adherence achievement.
ABSTRACT
Clozapine (CZP) is an atypical antipsychotic drug that does not appear to block striatal dopamine receptors. In six patients who met the criteria of HIV-associated psychosis and who had previously developed moderate parkinsonism as a result of the use of typical neuroleptic agents, CZP was added in an open, rising dose study. Subjects were evaluated at baseline after at least 7 days without neuroleptic drugs and then monthly for 3 months of the experimental treatment using three rating scales: Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), and motor examination of the Unified Parkinson's Disease Rating Scale (UPDRS). A significant reduction in psychopathology as represented in the BPRS total score (54.2 at baseline versus 23.9 at month 3) and CGI (2 and 8, respectively) was obtained with a mean CZP dose of 27.08 mg/day. Parkinsonism also improved by an average of 76.5% at the end of the study. One patient did not complete the study as a result of a progressive decrease in leukocyte count while on CZP. These preliminary results suggest that the pharmacologic properties of CZP may be of value in the management of HIV-psychotic patients.
